Publications by authors named "Mo-Ran Shi"
Article Synopsis
- Difficult-to-treat Rheumatoid arthritis (D2T RA) is defined by the lack of response to at least two different biologic drugs, leading to ongoing disease activity, prompting a systematic review of treatment options.
- The study reviewed 42 randomized controlled trials to evaluate the effectiveness and safety of various drugs, finding that tocilizumab, baricitinib, and olokizumab ranked highest in improving disease activity scores.
- The results suggest that tocilizumab, particularly at an 8 mg/4-week dosage, alongside rituximab, are effective and safe options for managing D2T RA, marking tocilizumab as a leading choice for treatment.
